ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026

Tazobactam

Beta-Lactamase Inhibitors

GB MHRA

Drug class: Beta-Lactamase Inhibitors
Availability: See label
Markets covered: 1
Products on record: 27

Overview

Tazobactam is an active pharmaceutical ingredient in the Beta-Lactamase Inhibitors group (J01CG). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	27	May 15, 2026

GBUnited Kingdom· MHRA

27 products

Uses

GBOfficial regulatory label· revised May 15, 2026[1]

1): Adults and adolescents • Severe pneumonia including hospital-acquired and ventilator-associated pneumonia • Complicated urinary tract infections (including pyelonephritis) • Complicated intra-abdominal infections • Complicated skin and soft tissue infections (including diabetic foot infections) Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Piperacillin/Tazobactam may be used in the management of neutropenic patients with fever suspected to be due to a bacterial infection.
Note:
Use for bacteraemia due to extended-beta-lactamase (ESBL) producing E. coli and K. 1. Children 2 to 12 years of age • Complicated intra-abdominal infections Piperacillin/Tazobactam may be used in the management of neutropenic children with fever suspected to be due to a bacterial infection.

Drug interactions

Known interactions involving Tazobactam. Select one for details. This list is informational and not a complete interaction checker.

Entecavir Probenecid

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL035510170 · revised May 15, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Tazobactam: Uses, Side Effects, Dosage - Drugvu

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 15, 2026[1]

The most commonly reported adverse reaction is diarrhoea (occurring in 1 patient out of 10). Among the most serious adverse reactions pseudo-membranous colitis and toxic epidermal necrolysis occur in 1 to 10 patients in 10,000. The frequencies for pancytopenia, anaphylactic shock and Stevens-Johnson syndrome cannot be estimated from the currently available data.
In the following table, adverse reactions are listed by system organ class and MedDRA-preferred term. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. System Organ Class Very Commo n (≥ 1/10) Common (≥ 1/100 to < 1/10) Uncommon (≥ 1/1,000 to < 1/100) Rare (≥ 1/10,000 to < 1/1,000) Frequency not known (cannot be estimated from available data) Infections and infestations candida infection* pseudomembra nous colitis Blood and lymphatic system disorders thrombocytope nia, anaemia* leukopenia agranulocytosi s pancytopenia*, neutropenia, haemolytic anaemia*, thrombocytosis *, eosinophilia* Cardiac disorders Kounis syndrome*,** Immune system disorders anaphylactoid shock*, anaphylactic shock*, anaphylactoid reaction*, anaphylactic reaction*, hypersensitivit y* Metabolism and nutrition disorders hypokalaemia Psychiatric disorders insomnia delirium* Nervous system disorders headache seizure* Vascular disorders hypotension, phlebitis, thrombophleb itis, flushing Respiratory, thoracic and mediastinal disorders epistaxis eosinophilic pneumonia Gastrointestin al disorders diarrho ea abdominal pain, vomiting, constipation, nausea, dyspepsia stomatitis Hepatobiliary disorders hepatitis*, jaundice Skin and subcutaneous tissue disorders rash, pruritus erythema multiforme*, urticaria, rash maculo- papular* toxic epidermal necrolysis* Stevens- Johnson syndrome*, dermatitis exfoliative, drug reaction with eosinophilia and systemic symptoms (DRESS)*, acute generalised exanthematous pustulosis (AGEP)*, dermatitis bullous, linear IgA disease*, purpura Musculoskele tal and connective tissue disorders arthralgia, myalgia rhabdomyolysi s* Renal and urinary disorders renal failure, tubulointerstiti al nephritis* General disorders and administratio n site conditions pyrexia, injection site reaction chills Investigations alanine aminotransfera se increased, aspartate aminotransfera se increased, protein total decreased, blood albumin decreased, blood glucose decreased, blood bilirubin increased, prothrombin time prolonged bleeding time prolonged, gamma- glutamyltransf erase increased Coombs direct test positive, blood creatinine increased, blood alkaline phosphatase increased, blood urea increased, activated partial thromboplastin time prolonged *ADR identified post marketing **Acute coronary syndrome associated with an allergic reaction Piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.
4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised May 15, 2026[1]

The selection of piperacillin/tazobactam to treat an individual patient should take into account the appropriateness of using a broad-spectrum semi-synthetic penicillin based on factors such as the severity of the infection and the prevalence of resistance to other suitable antibacterial agents.
g. cephalosporin, monobactam or carbapenem) and other allergens. Serious and occasionally fatal hypersensitivity (anaphylactic/anaphylactoid [including shock]) reactions have been reported in patients receiving therapy with penicillins, including piperacillin/tazobactam.
These reactions are more likely to occur in persons with a history of sensitivity to multiple allergens. Serious hypersensitivity reactions require the discontinuation of the antibiotic, and may require administration of epinephrine and other emergency measures.
8). 8). If patients develop a skin rash they should be monitored closely and Piperacillin/Tazobactam discontinued if lesions progress. Haemophagocytic lymphohistiocytosis (HLH) Cases of HLH have been reported in patients treated with piperacillin/tazobactam, often following treatment longer than 10 days.
g. fever, hepatosplenomegaly, hypertriglyceridaemia, hypofibrinogenaemia, high serum ferritin, cytopenias and haemophagocytosis). Patients who develop early manifestations of pathologic immune activation should be evaluated immediately.
If diagnosis of HLH is established, piperacillin/tazobactam treatment should be discontinued. Rhabdomyolysis has been reported with the use of Piperacillin/Tazobactam. If signs or symptoms of rhabdomyolysis are observed, Piperacillin/Tazobactam should be discontinued and appropriate therapy initiated.
Antibiotic-induced pseudomembranous colitis may be manifested by severe, persistent diarrhoea which may be life-threatening. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. In these cases, Piperacillin/Tazobactam should be discontinued.
Therapy with Piperacillin/Tazobactam may result in the emergence of resistant organisms, which might cause super-infections. Bleeding manifestations have occurred in some patients receiving beta-lactam antibiotics. These reactions sometimes have been associated with abnormalities of coagulation tests, such as clotting time, platelet aggregation and prothrombin time, and are more likely to occur in patients with renal failure.

This is not medical advice. Consult a qualified healthcare professional.